Sanofi Poised for Largest Biotech Acquisition in Years as It Eyes Insmed Deal
Sanofi is reportedly weighing a takeover of US biotech Insmed, a deal that could be its biggest in years and help offset a Dupixent sales slowdown.
POLICY WIRE — Paris, France — Sanofi appears to be positioning itself for a landmark biotech transaction as reports suggest the French pharmaceutical group is evaluating a bid for U.S. drugmaker Insmed.
The potential acquisition would mark the biggest deal Sanofi has pursued in the sector for several years, according to multiple industry outlets.
Insmed, known for its specialty respiratory and infectious‑disease portfolio, is developing a late‑stage candidate called Brinsupri that could become a significant revenue source if brought to market.
Market observers noted that Insmed shares surged after the takeover rumors surfaced, with Bloomberg, Reuters, Investor’s Business Daily and other sources confirming the heightened interest.
Analysts view the move as a strategic effort by Sanofi to counter a projected decline in sales of its blockbuster eczema therapy Dupixent, often described as a “Dupixent cliff,” and to broaden its pipeline with promising biotech assets.
Reporting by Policy-Wire (PW)




